Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II TRIAL OF RECOMBINANT INTERFERON-ALPHA-2A AND EFLORNITHINE INPATIENTS WITH RECURRENT GLIOMA
Autore:
BUCKNER JC; BURCH PA; CASCINO TL; OFALLON JR; SCHEITHAUER BW;
Indirizzi:
MAYO CLIN & MAYO FDN,DIV MED ONCOL,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT NEUROL ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,CANC CTR STAT ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,SURG PATHOL SECT ROCHESTER MN 55905
Titolo Testata:
Journal of neuro-oncology
fascicolo: 1, volume: 36, anno: 1998,
pagine: 65 - 70
SICI:
0167-594X(1998)36:1<65:PTORIA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEPLETION;
Keywords:
GLIOMA; EFLORNITHINE; INTERFERON; PHASE II; BRAIN NEOPLASM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
J.C. Buckner et al., "PHASE-II TRIAL OF RECOMBINANT INTERFERON-ALPHA-2A AND EFLORNITHINE INPATIENTS WITH RECURRENT GLIOMA", Journal of neuro-oncology, 36(1), 1998, pp. 65-70

Abstract

Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 10(6) units/m(2) subcutaneously days 3 to 7) and eflornithine (2.25 g/m(2) QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, butthe disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha pluseflornithine demonstrated no definite antitumor effects in this trial.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 08:31:36